Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity

Background Current influenza vaccines based on the hemagglutinin protein are strain specific and do not provide good protection against drifted viruses or emergence of new pandemic strains. An influenza vaccine that can confer cross-protection against antigenically different influenza A strains is highly desirable for improving public health. Methodology/Principal Findings To develop a cross protective vaccine, we generated influenza virus-like particles containing the highly conserved M2 protein in a membrane-anchored form (M2 VLPs), and investigated their immunogenicity and breadth of cross protection. Immunization of mice with M2 VLPs induced anti-M2 antibodies binding to virions of various strains, M2 specific T cell responses, and conferred long-lasting cross protection against heterologous and heterosubtypic influenza viruses. M2 immune sera were found to play an important role in providing cross protection against heterosubtypic virus and an antigenically distinct 2009 pandemic H1N1 virus, and depletion of dendritic and macrophage cells abolished this cross protection, providing new insight into cross-protective immune mechanisms. Conclusions/Significance These results suggest that presenting M2 on VLPs in a membrane-anchored form is a promising approach for developing broadly cross protective influenza vaccines.

[1]  A. Klimov,et al.  Modified M2 proteins produce heterotypic immunity against influenza A virus. , 1999, Vaccine.

[2]  Mark R. Soboleski,et al.  Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. , 2009, Vaccine.

[3]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[4]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[5]  T. Teyler.  Of Mice and Monkeys. , 1971 .

[6]  H. Heiken,et al.  The IgG Fc receptor family , 1998, Annals of Hematology.

[7]  R. Lamb,et al.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions , 1988, Journal of virology.

[8]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[9]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. , 1985, Cell.

[10]  S. Dow,et al.  Francisella tularensis Induces Aberrant Activation of Pulmonary Dendritic Cells1 , 2005, The Journal of Immunology.

[11]  J. Shiver,et al.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.

[12]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[13]  W. Fiers,et al.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments , 2009, Expert review of vaccines.

[14]  H. Grey,et al.  Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line , 1977, The Journal of experimental medicine.

[15]  R. Compans,et al.  Influenza vaccines based on virus-like particles. , 2009, Virus research.

[16]  K. Okuda,et al.  Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. , 2001, Vaccine.

[17]  C Oseroff,et al.  Human memory CTL response specific for influenza A virus is broad and multispecific. , 2000, Human immunology.

[18]  M. Prausnitz,et al.  Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin , 2009, PloS one.

[19]  J. Shiver,et al.  Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. , 2009, Virology.

[20]  Scott A. Brown,et al.  Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza , 2006, Clinical and Vaccine Immunology.

[21]  C. Davis,et al.  Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles , 2009, PloS one.

[22]  W. Fiers,et al.  CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. , 2008, Vaccine.

[23]  Jonathan Dushoff,et al.  Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Pekosz,et al.  Tyrosines in the Influenza A Virus M2 Protein Cytoplasmic Tail Are Critical for Production of Infectious Virus Particles , 2010, Journal of Virology.

[25]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[26]  J. Shiver,et al.  Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. , 2006, Journal of pharmaceutical sciences.

[27]  Gavin J. D. Smith,et al.  Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic , 2009, Nature.

[28]  P. Holt,et al.  Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity , 1991, European journal of immunology.

[29]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[30]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[31]  D. Metzger,et al.  Fc Receptor-Mediated Phagocytosis Makes a Significant Contribution to Clearance of Influenza Virus Infections1 , 2001, The Journal of Immunology.

[32]  M. Carroll,et al.  Natural Antibody and Complement Mediate Neutralization of Influenza Virus in the Absence of Prior Immunity , 2007, Journal of Virology.

[33]  S. Tompkins,et al.  Genetic control of immune responses to influenza A matrix 2 protein (M2). , 2010, Vaccine.

[34]  K. Legge,et al.  Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs , 2008, The Journal of experimental medicine.

[35]  T. Tumpey,et al.  Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. , 2006, Vaccine.

[36]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[37]  R. Lamb,et al.  Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. , 1991, Virology.

[38]  R. Compans,et al.  Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal Immunization , 2007, Journal of Virology.

[39]  R. Compans,et al.  Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles , 2006, Journal of Virology.

[40]  L. Otvos,et al.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse , 2007, Virology Journal.

[41]  W. Fiers,et al.  The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. , 2006, Vaccine.

[42]  R. Zinkernagel,et al.  Immunological Memory , 2006 .

[43]  W. Fitch,et al.  Predicting the evolution of human influenza A. , 1999, Science.

[44]  W. Fiers,et al.  An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2* , 2008, Journal of Biological Chemistry.

[45]  Larry R. Smith,et al.  Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge , 2007, Human vaccines.

[46]  R. Zinkernagel,et al.  Neutralizing antiviral B cell responses. , 1997, Annual review of immunology.

[47]  Q. Yao,et al.  Th Cell-Independent Immune Responses to Chimeric Hemagglutinin/Simian Human Immunodeficiency Virus-Like Particles Vaccine1 , 2004, The Journal of Immunology.

[48]  M. Neuberger,et al.  Activation of mouse complement by monoclonal mouse antibodies , 1981, European journal of immunology.

[49]  K. Mozdzanowska,et al.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. , 2006, Virology.

[50]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[51]  K. Schwarz,et al.  Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine design , 2008, European journal of immunology.

[52]  R. Compans,et al.  Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus , 2007, Journal of Virology.

[53]  R. Compans,et al.  Virus-Like Particle Vaccine Protects against 2009 H1N1 Pandemic Influenza Virus in Mice , 2010, PloS one.